An interventional study of SuperSonic image in Cardiovascular Diseases in Old Age, sponsored by French Cardiology Society. Recruiting at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by French Cardiology Society · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Heart Failure by French Cardiology Society — 3 open to participants now, 3 under way, none of them phase 3. Heart Failure · French Cardiology Society.
Among the 16 studies in Heart Failure by French Cardiology Society, this one is one of 2 that started in 2020, is one of 8 with no phase, and was the 11th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →3 of the 16 studies in Heart Failure by French Cardiology Society are open now, in 1 country. Recruiting first, the newest first:
French Cardiology Society · Sites in France
Ages 18+
French Cardiology Society · Sites in France
Ages 40–80
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2020.
This study's planned enrollment of 140 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 110 across the 8 interventional studies, 1,297 across the 8 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
French Cardiology Society is the lead sponsor of 85 studies on the registry; 16 are open to participants now.
2 of the studies in Heart Failure by French Cardiology Society that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03895541French Cardiology SocietyNoninvasive Elastography Evaluation of Myocardial Stiffness in Elderly Patients With Isolated Diastolic Heart Failure: New Diagnostic Tool? | 2026-12-31 |
| NCT07837349French Cardiology SocietyEvaluation of the Clinical Value of NT-proBNP (or BNP) Measurement, Alone or in Combination With the EPOF Questionnaire, for the Screening of Chronic Heart Failure (CHF) in Adults Aged 40 Years and Older Referred for a Cardiology Consultation Without Suspected CHF. | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Heart Failure by French Cardiology Society, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The new approach propose in this protocol is based on ultrafast ultrasound and remote palpation of tissue by ultrasonic radiation pressure. Ultrafast ultrasound of biological tissues is based on an innovative ultrasound imaging approach that can image very fast soft tissue events at a rate of several thousands of frames per second and provide quantitative mapping of the elasticity of the tissues. This current project aims is to focus on myocardial rigidity in diastole to better assess the function of the heart failure.
Diastolic heart failure or heart failure with preserved systolic function is the leading cause of heart failure in elderly subjects (more than 2/3 of heart failure in subjects over 60 years). Its main etiology is high blood pressure. Diagnosis of diastolic heart failure remains controversial in clinical practice. It is based on ultrasound and biological criteria. These are mainly acute edema of the lung for patients with preserved Ejection Fraction and high Brain Natriuretic Peptid. It is now recognized that the "primum movens" of this type of heart failure is the increase in myocardial stiffness secondary to left ventricular hypertrophy. The noninvasive evaluation of this parameter would allow a more accurate and reliable diagnosis since it does not depend on the loading conditions, unlike the heart failure and the trans-mitral Doppler). However, the absence of a non-invasive tool for the direct evaluation of diastolic (so-called passive) rigidity prevents the use of this diagnostic parameter. Investigators propose here to non-invasively evaluate the myocardial stiffness in the elderly patient with diastolic heart failure thanks to a new imaging tool using an innovative ultrasonic technology, the ultrafast-echo associated with its elastographic mode "ShearWave Imaging". Investigators have been working for several years in collaboration with the Langevin Institute on this technology, which has recently been validated on experimental models. Its principle is based on the creation of a shear wave from a standard ultrasound probe and the calculation of the velocity of this wave thanks to the very high temporal resolution of the ultrasound system, this speed being correlated to the myocardial rigidity. The human study was recently made possible by the development of a phased array probe with the ability to work with the elastography mode ("ShearWave Imaging").
The criteria were revised on the registry on Oct 9, 2026. See what changed
General inclusion criteria:
Specific inclusion criteria:
HFpEF group (preserved ):
At least one of the following:
HFmrEF group (moderately reduced left ventricular ejection fraction):
At least one of the following:
HFrEF group (reduced left ventricular ejection fraction):
- Diagnosis of heart failure with reduced ejection fraction according to the ESC Guidelines.
General exclusion criteria:
Specific exclusion criteria:
HFpEF group:
HFmrEF group:
- Associated pulmonary disease.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patient will have the same intervention. They will be stratified regarding their degree of heart failure gravity. * HFpEF : 80 patients (including 25 with cardiac amyloidosis) * HFmrEF : 30 patients * HFrEF : 30 patients
Diagnostic Test: SuperSonic image
3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
Myocardial stiffness assessment by elastography
Assessment of myocardial stiffness using non-invasive ultrasound elastography, and comparison of the elastography-derived myocardial stiffness parameters with conventional echocardiographic and biological parameters used for the diagnosis of diastolic heart failure.
Time frame: Day 1
Norms estimation of myocardial rigidity
Estimation of physiological and pathological norms of myocardial rigidity by elastography to detect and diagnose heart failure according to the left ventricular ejection fraction phenotype (HFpEF, HFmrEF and HFrEF).
Time frame: Day 1
Characterization of myocardial stiffness in patients with HFpEF
Evaluation of myocardial stiffness assessed by elastography in a larger population of patients with heart failure with preserved ejection fraction (LVEF ≥50%), including characterization of patients with and without documented cardiac amyloidosis.
Time frame: Day 1
Diagnostic parameters of SWI in cardiac amyloidosis
Evaluation of differences in myocardial stiffness and other ShearWave Imaging -derived parameters between patients with HFpEF with and without documented cardiac amyloidosis, in order to further characterize the diagnostic performance of ShearWave Imaging
Time frame: Day 1
Safety of cardiac elastography
patient monitoring (electrocardiogram scope and constants every10 min) for 30 minutes post-examination associated with a "comfort questionnaire" to be completed by the patient after the examination
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Dec 2026, 83 months after the start.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 83 months is above that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2025 → Dec 2026 and completion Dec 2025 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French Cardiology Society